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Erythropoiesis requires a combination of ubiquitous and tissue-specific 
transcription factors. Here, through DNA affinity purification followed by mass 
spectrometry, we have identified the widely expressed protein MAZ (Myc-
associated zinc finger) as a transcription factor that binds to the promoter of the 
erythroid-specific human α-globin gene. Genome-wide mapping in primary 
human erythroid cells revealed that MAZ also occupies active promoters as well 
as GATA1-bound enhancer elements of key erythroid genes. Consistent with an 
important role during erythropoiesis, knockdown of MAZ in primary human 
erythroid cells impairs erythroid differentiation, and genetic variants in the MAZ 
locus are associated with clinically important human erythroid traits. Taken 
together, these findings reveal the Zinc-finger transcription factor MAZ to be a 
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Over the last three decades, studies of the α- and β-globin gene clusters have 
contributed to our understanding of some of the fundamental principles of mammalian 
gene regulation, including RNA stability, termination of transcription, and the 
identification of remote regulatory elements1. A complex network of DNA sequence 
elements, chromatin accessibility, histone modifications, and transcription factor (TF) 
occupancy orchestrates expression of globin genes, which are exclusively expressed 
in erythroid cells 2. Both proximal regulatory regions (promoters) and distal regulatory 
elements (enhancers) are required for the initiation of α-globin (HBA) and β-globin 
(HBB) gene expression in erythroid cells. When active, these regulatory elements are 
characterised by the presence of DNase I hypersensitivity sites (DHS) and active 
histone modifications. A small group of lineage-restricted TFs including GATA binding 
protein 1 (GATA1), T cell acute lymphocytic leukemia 1 protein (TAL1), and Erythroid 
Krüppel-like factor (EKLF; henceforth referred to as KLF1) act as erythroid ‘master 
regulators 3, by binding to both promoters and enhancers of the globin genes as well 
as to other genes important for erythropoiesis, thereby significantly contributing to their 
expression [reviewed in 2,4,5]. 
Genetic and biochemical dissection of gene regulation programs has revealed that 
transcription of cell type-specific genes is usually achieved through synergy and 
cooperation between ubiquitously expressed TFs and tissue- or developmental stage-
specific TFs 6,7. Although this concept is well established, the mechanisms of 
interactions and relationships between tissue-specific and ubiquitous TFs are 
generally lacking. Moreover, the broad range of phenotypic abnormalities associated 
with mutations/alterations in ubiquitously expressed regulators preclude dissecting 
their roles in specific processes and determining their contribution to disease states. 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted May 10, 2020. ; https://doi.org/10.1101/2020.05.10.087254doi: bioRxiv preprint 
4 
 
Here, we have carried out an unbiased screen for proteins that bind to adjacent GC-
rich motifs in the promoter of the duplicated α-globin genes (HBA2 and HBA1) in 
human erythroid cells, combining electrophoretic mobility shift assays (EMSAs), DNA 
affinity purification, and mass spectrometry. This screen identified Myc-Associated 
Zinc-finger protein (MAZ) as a direct binder of the promoter region of the human α-
globin gene in vitro and in vivo.  Knockdown of MAZ in primary human erythroid cells 
led to both reduction of α-globin expression and a block of erythroid differentiation. 
Moreover, variants in the MAZ gene itself and its promoter region are associated with 
clinically important human erythroid traits. By ChIP-seq in primary human erythroblasts 
we showed that MAZ is enriched at transcription start sites (TSSs) of transcriptionally 
active genes and distal regulatory elements where it recognises a canonical G3(C/A)G4 
binding motif. Erythroid-specific MAZ signal is enriched at promoters and enhancers 
of genes associated with erythropoietic disorders. We found that MAZ erythroid-
specific binding sites frequently colocalize with GATA1, a key regulator of 
erythropoiesis, particularly at enhancer elements, suggesting functional synergy 
between these two transcription factors. Together our findings have identified MAZ as 
an important regulator of the erythroid differentiation program. 
 
RESULTS 
A novel DNA-protein complex occupies the distal promoter region of the human 
HBA genes. 
Transcriptional activation of the HBA genes during erythroid differentiation is 
associated with localised relaxation of chromatin structure, which is observed 
experimentally as a DHS immediately upstream (promoter region) of the adult HBA 
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genes (chr16: 172k-176k, Suppl. Figure 1A) specifically in erythroid cells8. In order to 
map chromatin accessibility within this erythroid-specific DHS at a higher resolution 
than provided by DNase- and ATAC-seq approaches, intact nuclei isolated from cells 
expressing a-globin (the erythroid cell line K562) and not expressing a-globin (EBV-
transformed B lymphoblast cell line) were digested with low concentrations of selected 
restriction enzymes. The extent of digestion reflects accessibility of the specific 
recognition sites and was assessed by Southern blotting (Suppl. Figure 1B). This 
assay revealed that the region of erythroid-specific sensitivity extends from -220 bp 
(FokI site) to +35 bp (NcoI site) relative to the TSS of the HBA genes (Suppl. Figure 
1B).  
In order to characterise protein binding across this hypersensitive region, we carried 
out electrophoretic mobility shift assays (EMSAs) using a series of overlapping 
oligonucleotide probes to compare in vitro binding proteins in nuclear extracts 
prepared from the same erythroid (K562) and non-erythroid (EBV) cells. 
Oligonucleotide probes were specifically placed at positions suggestive of protein 
binding by in vivo dimethyl-sulfate (DMS) footprinting assays reported previously 
(Figure 1A, Table 1) 9.  
We observed band shifts for five out of seven probes used (Figure 1B). Previous motif 
analysis had suggested potential binding motifs for SP1 (-121/-116, -61/-56), CBF (-
72/-65), Nuclear Factor I (NF1) (-85/-72), and a-inverted repeat protein (a-IRP) (-51/-
42) 9 (Table 1). Gel supershift assays, in which nuclear extracts were pre-incubated 
with anti-CBF or anti-NF1 antibodies, affect the retarded bands at probes 7/8 and 9/10 
respectively, confirming that these sites are indeed bound by CBF and NF1 (Figure 
1B, lanes 13 and 17, respectively). Interestingly, complex binding patterns comprised 
of four shifted bands were observed at two neighbouring GC boxes situated at -100/-
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83 (probe 11/12) and -128/-111 (probe 13/14). These GC boxes have a highly similar 
sequence (Suppl. Figure 2A) and were able to cross-compete with each other in 
competition assays (Suppl. Figure 2B), suggesting that they are likely to be bound by 
the same proteins. Interestingly, while the most heavily retarded bands (labelled a, b 
and c in Figure 1B) were detected in both K562 and EBV nuclear extracts, the faster 
migrating band (d) was observed only in K562 cells. This factor bound more strongly 
to probe 13/14 than to 11/12 (Figure 1B, compare lanes 20 and 23), a finding that was 
confirmed in competition assays (Suppl. Figure 2B). Gel shifts carried out with nuclear 
extracts from other cell types revealed that band (d) was the most abundant complex 
in primary human erythroblasts but was either not detected or weak in a range of non-
erythroid cells types (HT-29, SW13, HepG2, and HeLa) (Figure 1C).  
The probe 13/14 (covering -128/-111 region) contains a predicted binding motif for the 
Krüppel-like zinc-finger transcription factor Sp1 9 (Table1). We found that the binding 
of all four proteins to probe 13/14 was sensitive to the presence of the zinc-chelating 
agent EDTA (Suppl. Figure 3A), consistent with Zn-finger-dependent binding. In 
contrast, binding of the non-Zn-finger protein CBF to probe 7/8 was not affected by 
EDTA (Suppl. Figure 3A). To identify the protein responsible for these bands on probe 
13/14, we carried out gel supershift reactions using antibodies against candidate Zn-
finger proteins (Sp1, Sp3, Krüppel-like factor 1 (EKLF), and Krüppel-like factor 3 
(BKLF)). These experiments revealed bands (a), (b) and (c) to be Sp1, Sp3 and KLF3, 
respectively (Figure 1D). These findings are consistent with the detection of proteins 
(a), (b) and (c) in both erythroid and non-erythroid nuclear extracts (Figure 1C), since 
Sp1, Sp3 and BKLF are all widely-expressed TFs and have previously been shown to 
regulate a-globin expression 10,11. In contrast, the binding of protein (d) to probe 13/14 
was not strongly affected by any of the antibodies tested. Taken together, these 
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experiments have revealed an erythroid-enriched complex at neighbouring sites in the 
-128/-90 region upstream of HBA genes.  
A mass spectrometry-based screen identifies MYC-associated Zn-finger protein 
MAZ as a factor binding at the a-globin promoter   
In order to identify the factor responsible for band (d), we carried out a protein affinity 
purification screen, using probe 13/14 as the bait (Figure 2A).  As a negative control, 
we designed a mutant version of probe 13/14 (M3) in which a central guanidine was 
changed to thymidine, preventing formation of band (d) while also depleting binding of 
Sp1, Sp3 and BKLF (Suppl. Figure 3B). To carry out this screen, K562 nuclear extracts 
were incubated with desthiobiotin-modified DNA probes, protein-DNA complexes were 
purified using streptavidin beads, and eluted proteins were subjected to mass 
spectrometry (Figure 2A)12. Of the 390 proteins identified (Supplemental Table 1), one 
of the most interesting candidates to emerge was the Myc-associated Zn-finger protein 
MAZ, a C2H2-type Zinc finger protein which has been previously shown to bind in vitro 
to a G-rich consensus motif (G3AG3) 13-15 (Figure 2B). 
In order to investigate whether MAZ is indeed the protein responsible for band (d), we 
performed siRNA-mediated knockdown (KD) of MAZ in K562 cells. Depletion of MAZ 
protein was associated with reduction of band (d) in the gel shift assays (Figure 2C). 
Conversely, expression of exogenous MAZ protein in COS7 cells was associated with 
strong enrichment of band (d) (Figure 2D). Binding of the over-expressed MAZ protein 
resulted in a depletion of the Sp3 gel shift, indicating competition for binding under 
these in vitro conditions. Altogether, these experiments confirm that MAZ is indeed the 
protein responsible for band (d) and indicate that MAZ binds to neighbouring GC boxes 
at -100/-83 and -128/-111 within the human a-globin promoter in vitro.  
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In order to confirm binding by MAZ at the active HBA promoter in vivo, we carried out 
ChIP-qPCR experiments using a previously described series of qPCR amplicons 
throughout the HBA locus10. Whereas binding was absent or low in non-expressing 
cells (EBV lymphoblast), strong enrichment of MAZ was observed at the HBA 
promoter and gene body in cells expressing HBA, with the highest enrichment 
observed in primary erythroid cells (Figure 2E). In these primary cells, MAZ was also 
enriched at the important distal regulatory element of the a-globin locus (MCS–R2). 
We further investigated the dynamics of MAZ recruitment to the a-globin genes during 
erythroid maturation in primary erythroblast differentiation cultures (Suppl. Figure 4A-
C). During differentiation, expression of the adult globin genes HBB and HBA is 
strongly upregulated, peaking in intermediate and late stage erythroblasts (Suppl. 
Figure 4D, see also 16). Concomitantly with the strong upregulation of α-globin 
expression, MAZ was dynamically recruited to the HBA promoter and genes in these 
cultures (Suppl. Figure 4E). Altogether, our results indicate that MAZ binds to the 
active human HBA locus both in vitro and in vivo.   
MAZ is required for erythroid differentiation and is associated with clinical 
erythroid-related traits  
To investigate the functional significance of MAZ during erythroid differentiation, we 
used shRNA to deplete MAZ expression in differentiating primary human erythroid 
cultures. FACS analysis revealed an impaired differentiation of primary erythroid 
cultures infected with the MAZ shRNA lentivirus, with cells accumulating at the CFUe 
and pro-erythroblast (CD71+GPAlo) stages, and failing to differentiate towards 
intermediate erythroblasts (CD71+GPA+) (Figure 3A, B). This impaired differentiation 
could also be observed as a deficiency of haemoglobinisation (Figure 3C). Knockdown 
of MAZ expression was further associated with downregulation of expression of a-
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globin (Figure 3D). While this downregulation of a-globin is likely to also arise indirectly 
due to the impaired differentiation, expression of a-globin was more affected than b-
globin (where no binding of MAZ was observed in erythroid cells, see below), 
consistent with MAZ playing a direct regulatory role at the a-globin locus.  
Given these findings suggesting a previously unknown for MAZ during erythroid 
differentiation, we further investigated whether human genetic variants in the MAZ 
gene are associated with clinically important erythroid traits. We analysed the 
GeneATLAS database that reports associations between 778 traits and millions of 
DNA variants 17. Out of 25 erythroid-related traits in the GeneATLAS (Suppl. Table 2), 
eight traits (32%) were associated with three variants in the MAZ gene or promoter 
region (rs11559000, rs572982482, rs72798129) with p-value 10-2-10-5 (Figure 3E). 
Taken together, these findings indicate that MAZ is an important factor in the erythroid 
differentiation program and suggest that this locus contributes to clinically relevant 
erythroid traits.  
MAZ occupies TSS and binds directly to DNA through G3(C/A)G4 motif 
Following from our findings at the HBA locus, we expanded our analysis by 
investigating binding of MAZ genome-wide in primary human erythroid cells by 
carrying out ChIP-seq (Suppl. Figure 5A-B). As previously observed by ChIP-qPCR 
(Figure 2E), MAZ was strongly enriched at both HBA2/1 promoters as well as, to a 
weaker extent, at the MCS-2 remote regulatory element (Figure 4A, top). In contrast, 
very low binding of MAZ was detected at the promoter and regulatory elements (locus 
control regions; LCR) of the b-globin gene cluster (Figure 4A, bottom). Genome-wide, 
we identified 10 088 MAZ binding sites in primary erythroid cells (Suppl. Figure 5C). 
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While the majority of MAZ binding sites (65%) were located at promoter regions 
(Figure 4B), the average MAZ enrichment was comparable for peaks in the promoter 
regions, intergenic, and genic regions (Suppl. Figure 5D). Overall, MAZ was present 
at least at one TSS of 28% (5466/19646) of protein-coding genes. Comparison with 
published ChIP- and ATAC-seq datasets from erythroid cells8,18-20 (Suppl. Table 6) 
revealed that MAZ binding sites are located in regions of high chromatin accessibility 
(as detected by ATAC-seq) that are enriched for activating histone modifications 
(H3K4me3, H3K27ac) and Pol II but depleted of the repressive histone mark 
H3K27me3 (Figure 4C). Taken together, these results indicate that MAZ is enriched 
around TSS of a large proportion of transcriptionally active genes in erythroid cells.  
In order to identify motifs contributing directly to MAZ binding, we used the MEME 
software suite 21 to discover de novo enriched sequence motifs among a training set 
consisting of the 500 highest ranked MAZ peaks 22. Overall, six enriched motifs were 
detected in the MAZ erythroblast training dataset (E-value <0.01) (Figure 4D). The 
most significant motif found, G3(C/A)G4, is contained within the 13/14 probe derived 
from the HBA promoter used to identify MAZ in the MS screen, and was similar to the 
published canonical MAZ motif G3AG3 23. This canonical motif was present in 92% of 
all MAZ peaks (see methods and Figure 4D), and was the only enriched motif with a 
narrow unimodal central enrichment in the peaks and a large maximum site probability 
(Figure 4E), suggesting that the vast majority of MAZ genomic binding in erythroblasts 
is due to direct DNA binding of MAZ to this canonical DNA sequence motif. In 
agreement with these observations, mutations within this core G3CG4 motif present in 
the 13/14 probe prevented MAZ binding in vitro, while mutations outside this core motif 
had little effect (Suppl. Figure 6). Furthermore, the 11/12 probe, which exhibits lower 
affinity for MAZ (Figure 1B and Sup Fig. 2C), contains a less-perfect version of this 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted May 10, 2020. ; https://doi.org/10.1101/2020.05.10.087254doi: bioRxiv preprint 
11 
 
core motif than the 13/14 probe (Suppl. Figure 6). The second most abundant motif 
detected in our MAZ training set was a GGAGGA-containing motif. This motif was 
present in 31% of MAZ peaks, but did not exhibit central localisation, suggesting it may 
contribute to MAZ binding in a cooperative manner. The enrichment of this motif is 
consistent with the previous reports demonstrating binding by MAZ to GGA repeats 
with a high propensity to form G4-quadruplexes 24-27.  
Erythroid-specific MAZ binding sites are associated with the promoters of key 
erythropoiesis genes  
To gain further insight into the specific role of MAZ during erythroid differentiation, we 
compared the genome-wide profile of MAZ binding in primary erythroblasts with MAZ 
ChIP-seq profiles from five human non-erythroid cell lines (HepG2, GM12848, MCF-
7, IMR90, A549) generated by the ENCODE consortium 28,29 (Suppl. Table 6). 
Comparison of MAZ peaks identified in these six cell types revealed that, as expected 
for a housekeeping transcription factor, a large proportion of MAZ peaks are shared 
between at least two different cell types (so called “common” peaks, (n=8308) (Figure 
5A). However, between 8 and 40% of the MAZ peaks observed in a given cell line 
were not observed in any other cell type (Figure 5A, Suppl Table 3), suggesting that 
as well as regulating housekeeping functions, MAZ also plays an important role in the 
control of cell-type restricted gene expression programs. Consistent with this, Pearson 
correlation coefficients for these datasets indicated that MAZ exhibited globally distinct 
binding profiles in the different cell types (correlation coefficient < 0.85 for all pairwise 
comparisons) (Figure 5B). In particular, 18% of MAZ peaks observed in erythroid cells 
were not shared with other cell types (1780 peaks, termed “erythroid-specific peaks”). 
Comparison with gene expression profiles 20 revealed that MAZ binds 41% (218/528) 
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of promoters of genes with erythroid-specific expression. Gene ontology analysis 
revealed that genes with a TSS bound by MAZ in an erythroid-specific manner were 
significantly associated with erythroid differentiation and blood haemostasis functions 
(Figure 5C) as well as phenotypes associated with haematological diseases (Figure 
5D). We also investigated MAZ binding at genomic loci which have previously been 
linked to clinical erythroid phenotypes in GWAS studies. Out of 31 genes associated 
with erythropoiesis 30, MAZ peaks were present on the promoters of 21 of them (Suppl. 
Table 4). Interestingly, among these genes with promoters bound by MAZ in an 
erythroid-specific manner were the TFs GATA1 and KLF1, master regulators of 
erythropoiesis (Suppl. Table 4 and Suppl. Figure 7). Taken together, these findings 
indicate that MAZ binds to the promoters of genes with key roles in erythroid 
differentiation and homeostasis.  
 
Erythroid-specific MAZ signal is enriched on GATA1-bound enhancers 
Interestingly, the common and erythroid-specific peaks of MAZ displayed distinct 
localisation relative to genomic features (Figure 6A). While the majority (71%) of 
common peaks were localised at promoter regions, only 24% of the MAZ erythroid 
specific peaks were located at promoters. In contrast to common MAZ peaks, 
erythroid-specific MAZ peaks were enriched at intergenic (24%) and intronic (40%) 
sites, suggesting that MAZ may play a particularly important role at erythroid-specific 
distal regulatory elements. Comparison with our previously published catalogue of 
erythroid enhancers 20 confirmed that 27% of the erythroid-specific MAZ peaks 
coincided with known enhancer elements, compared with only 7% of the “common” 
peaks. Consistent with this observation, we observed enrichment of the enhancer-
associated histone modification H3K4me1 on erythroid-specific non-TSS MAZ peaks, 
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but not on common non-TSS MAZ peaks, with H3K4me3 following the reverse trend 
(Figure 6B).  Taken together, these findings suggest that erythroid specific binding of 
MAZ is particularly important at distal enhancer elements.  
Ubiquitous and lineage specific factors often work together at proximal and distal 
regulatory sequences. As such, we explored the association between MAZ and the 
erythroid master regulator GATA1 in primary erythroid cells. Overall, 48% (854/1778) 
of erythroid-specific MAZ binding sites overlapped with GATA1 binding sites, 
consistent with a functional cooperative interaction between these two factors. 
Interestingly, this co-association between MAZ and GATA was particularly prominent 
within erythroid enhancer regions, with GATA1 signal being particularly elevated at 
erythroid MAZ peaks within enhancers and conversely, MAZ signal being stronger at 
GATA1 enhancer peaks (Figure 6C). Taken together, these findings are consistent 
with a particular functional cooperativity between MAZ and GATA1 at erythroid 
enhancer elements.   
 
DISCUSSION 
In this study, we have identified the ubiquitously-expressed Zn-finger protein MAZ as 
a factor binding to neighbouring GC-rich sites within the human a-globin promoters. 
ChIP and ChIP-seq experiments subsequently confirmed in vivo binding of MAZ to the 
active HBA genes as well as to promoters and enhancers of other key genes within 
the erythroid differentiation pathway and to genomic loci linked to clinical erythroid 
phenotypes. Moreover, erythroid-specific binding of MAZ was enriched at distal 
regulatory enhancer elements, where it frequently co-associated with the erythroid 
master-regulator GATA1 and knockdown of MAZ impaired erythroid differentiation in 
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ex vivo primary cultures. We further showed that genetic variants within the MAZ locus 
were associated with approximately one third of human phenotypic erythroid traits. 
Taken together, these findings reveal a previously unrecognised role for MAZ in the 
erythroid differentiation program.  
MAZ has not previously been shown to play an important role in the erythroid lineage. 
Germline deletion of MAZ in mice results in perinatal lethality 31, as might be expected 
for a ubiquitously expressed TF. MAZ knockdown in a primary erythroid differentiation 
culture system strongly affects HBA expression whereas expression of HBB was less 
affected. This is consistent with our ChIP-seq data showing binding of MAZ to the HBA 
promoters and distal regulatory elements and support a direct role for MAZ at this 
locus. Since our experiments indicate impaired differentiation of primary erythroid 
cultures infected with the MAZ shRNA lentivirus, inducible knockdown or knockout 
approaches will be needed to precisely determine the role of MAZ at specific stages 
of erythroid maturation.  
Through integration of MAZ binding profiles in different cell types, we observed both 
common and erythroid-specific MAZ binding sites. Erythroid-specific MAZ binding is 
observed at the promoters of GATA1 and KLF1, encoding master-regulators of the 
erythroid lineage. MAZ binding is also enriched at distal regulatory elements, which 
are considered to be primary determinants of tissue-
specific gene expression programs18,32. Importantly, it has been shown that the 
activity of erythroid enhancer elements cannot be predicted based on the binding of 
the master regulators of erythroid differentiation, GATA1 and TAL1, alone 18. In 
contrast, combinatorial co-occupancy of enhancers by both lineage-specific and 
ubiquitously expressed transcription factors is a more reliable indicator of enhancer 
activity and cell-specific expression18,32,33. Our findings suggest that binding of MAZ 
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together with lineage-restricted factors such as GATA1 might be an important step in 
the activation or maintenance of many erythroid enhancer elements. 
The vast majority (92%) of both shared and erythroid-specific MAZ peaks contain the 
canonical G3CG4 motif, indicating that MAZ binds DNA directly in both cases. 
Consistent with previous reports 24-27, our analysis of MAZ whole genome binding also 
indicated that a likely G4-forming motif (GGAGGA) contributes to MAZ binding, 
although our data suggests that this motif makes only a secondary contribution to MAZ 
binding affinity.     
At present, it is unclear how binding of MAZ to its target sites is regulated. In particular, 
while MAZ is a ubiquitously expressed protein whose levels do not change 
dramatically during erythroid differentiation (data not shown), we observed differential 
in vitro binding by MAZ to the 13/14 probe in gel shift assays, as well as a highly 
dynamic recruitment of MAZ to the HBA locus in primary erythroid cultures, suggesting 
that its binding is not primarily regulated at the level of expression. Western blot with 
α-MAZ antibody detected several bands in K562 cells, which were sensitive to MAZ 
shRNA (Figure 2C), suggesting the possibility that MAZ is subject to post-translational 
modifications in these cells. Interestingly, it has been shown in other cell types that 
phosphorylation at Ser480 (by casein kinase II) 34 or at Ser187 and Thr386 (by protein 
kinase A), increases the DNA-binding and transcriptional activation properties of 
MAZ35. MAZ can also be phosphorylated at Thr71 downstream of the Mitogen-
activated protein (MAP) kinase signalling pathway, and this phosphorylation is critical 
for activation of MAZ in response to inflammatory cytokines36. In the future it will be 
important to characterise how post-translational modifications regulate MAZ activity at 
the HBA locus and during erythroid differentiation, as well as the upstream signalling 
pathways involved. Interestingly, our data demonstrate that the sites bound by MAZ 
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within the HBA promoter can also be bound in vitro by other KLFs, including SP1, SP3 
and BKLF, suggesting the possibility of a crosstalk between these factors in regulating 
the expression of α-globin. Indeed, complex cross-regulatory interactions involving 
MAZ and Sp1 have also been reported at other promoters 37,38. We also found that 
these factors compete for the same binding site in our in vitro conditions. It is of interest 
that the expression of SP1 decreases markedly during erythroid differentiation 39 and 
that this decline correlates well with the dynamic recruitment of MAZ to the HBA 
promoters that is observed in primary erythroid differentiation cultures. These 
observations suggest that MAZ may bind to the HBA promoters in a commensurate 
manner when SP1 levels decline during erythroid differentiation, and that this 
replacement of SP1 by MAZ during the late stages of erythroid differentiation 
correlates with the maximal activation of the HBA genes. In the future it will be 
important to explore this potential crosstalk between SP1 and MAZ at the HBA 
promoters and how it plays out at the genome-wide level during erythroid 
differentiation.  
Overall, this study serves as an example of how a precise molecular characterisation 
of protein binding at a single regulatory element can be combined with an unbiased 
mass-spectrometry screen to identify new trans-acting regulators. This approach has 
revealed the Zn-finger transcription factor MAZ as a previously-unrecognised regulator 
of the erythroid differentiation program, which may be important for human erythroid 
phenotypic traits.  
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Cell lines and primary erythroid cells 
Primary erythroid cells and newly generated EBV-infected B-lymphoblasts were 
obtained as previously described 39. Cell lines (K562, HT29, HeLa, SW13 and COS7) 
were cultured in RPMI 1640 supplemented with 10% FBS. For siRNA-mediated 
knockdown of MAZ, K562 cells were transfected with MAZ SMARTPool siRNA or Non-
targeting control pool siRNA (Dharmacon) using Lipofectamine according to the 
manufacturer’s instructions, and cells were harvested after 4 days. For overexpression 
of MAZ, COS7 cells were transfected with the plasmid pcDSAF-1, which expresses 
full length MAZ (SAF-1) cDNA under the control of the CMV promoter 40. Cells were 
transfected using Lipofectamine according to the manufacturer’s instructions and were 
harvested after 30 h.     
Electrophoretic mobility-shift assay (EMSA)  
Nuclear extracts were performed as described 41 except that nuclei were incubated in 
buffer C for 30 min. Protein concentration was determined using the Qubit Protein 
Assay Kit (ThermoFisher). Oligonucleotide probes (Table 1) were designed to have 
an additional 5’GG overhang on each end after annealing and were labelled by filling 
in with the large Klenow fragment of DNA Polymerase I in the presence of [α-32P]-dCTP 
as described by the manufacturer (New England Biolabs). For gel shift reactions, 5 μg of 
nuclear extract was incubated with 1 ng radiolabelled probe (>10,000 cpm) in buffer [10 
mM HEPES (pH 7.8), 50 mM potassium glutamate, 5 mM MgCl2, 1 mM EDTA, 1 mM 
dithiothreitol, 0.5 μg of poly(dI-dC), 10 μg of bovine serum albumin, 1 mM ZnSO4, 5% 
glycerol] for 30 min on ice. For competition experiments, unlabelled competitor 
oligonucleotides were added to the binding reactions at 100 X molar excess. For gel 
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supershift experiments, antibodies were incubated with nuclear extract for 20 min on 
ice prior to the addition of the radiolabelled probe. Antibodies used in supershift 
experiments were as described in previous ChIP studies 10 . Following binding, 
samples were subjected to electrophoresis at 4°C for 2.5 h at 12 V/cm on a native 
polyacrylamide gel (6% [19:1] bis:acrylamide in 0.5 X Tris-borate-EDTA). The gels were 
dried and analysed using a Storm 860 Molecular Imager (Molecular Dynamics Ltd).  
shRNA knockdown in primary erythroid cultures 
Lentiviral constructs (pLKO.1) expressing MAZ-specific (clone TRCN0000015343) or 
non-targeting scrambled shRNAs were obtained from Dharmacon. These constructs 
express the shRNA from the human U6 promoter and the Puror gene from the hPGK 
promoter. Lentiviral preparations were prepared using standard techniques by co-
transfection of 293T cells with the lentiviral construct together with pMDLg/pRRE and 
pMD2.G using Fugene (Roche). Culture supernatants were harvested at 72 h after 
transfection and concentrated by ultracentrifugation using standard techniques. For 
lentiviral-mediated knockdown experiments, primary erythroid differentiation cultures 
were carried out essentially as described in Leberbauer et al., 42 with the following 
modifications. Peripheral blood mononuclear cells were cultured for 8 days in 
erythroblast expansion medium (StemSpan™ SFEM medium (Stem Cell 
Technologies) supplemented with Epo (2 U/mL), IGF-1 (40 ng/mL), SCF (100 ng/mL) 
(all cytokines from Peprotech), dexamethasone (1 μM, Sigma) and cholesterol-rich 
lipids (40 μg/mL, Sigma)). Cells were infected with concentrated lentivirus for 24 h in 
wells pre-coated with Retronectin (0.2 mg/ml; Takara) in expansion medium 
supplemented with protamine sulfate (10 µg/ml). The cells were seeded in fresh 
complete medium supplemented with cyclosporine A (1 mg/ml) for 24 h prior to 
selection with puromycin (1 µg/ml) for 48 h. After removing Puromycin, cells were 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted May 10, 2020. ; https://doi.org/10.1101/2020.05.10.087254doi: bioRxiv preprint 
19 
 
cultured for further 3 days in expansion medium containing cyclosporine prior to 
harvesting for FACS and RNA (total 15 days in culture).     
  
Mass Spectrometry 
For proteomics analysis, the DNA baits corresponding to oligonucleotide 13/14 WT 
and 13/14 M3 with a TT/AA-overhang were annealed, phosphorylated, ligated and 
purified as previously described12. The desthiobiotinylated oligonucleotides were 
coupled to Streptavidin Dynabeads MyOne C1 (Life Technologies) for 60 min at room 
temperature and excess oligonucleotides removed by washing. The oligonucleotide 
coupled streptavidin beads were incubated with 250 µg of K562 nuclear extract diluted 
in PBB buffer (150 mM NaCl, 50 mM Tris–HCl pH 8.0, 10 mM MgCl2, 0.5 % Igepal 
CA630, Complete Protease Inhibitor without EDTA (Roche)) for 2 hours at 4°C under 
slight agitation. Non-bound proteins were removed by washing three times with PBB 
buffer and the bound DNA-protein complexes liberated from the streptavidin beads 
with 200 µl of a 16 mM biotin/50 mM ABC (pH 8.0) solution. The complexes were 
precipitated with pure ethanol overnight at room temperature. The pellet was 
resuspended in 50 µl 8M urea and first digested with LysC (Wako) for 3 hours and 
subsequently diluted to 250 µl with 50mM ABC buffer and digested with 200 ng trypsin 
overnight, both at room temperature. The tryptic peptides were loaded onto an SCX 
StageTip43 and stored until the MS measurement.  
The tryptic peptides were fractionated on an in-house packed 25 cm microcapillary 
column (Reprosil 3.0 µm; Dr. Maisch GmbH) in a 125 minute gradient from 5 to 60 % 
acetonitrile. The MS measurement was performed on an LTQ Orbitrap XL (Thermo) 
with a top5 DDA method using CID fragmentation. The MS data was processed with 
MaxQuant44 version 1.0.12.5 using the human Uniprot database.  
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RNA was extracted with Tri reagent (Sigma) according to the manufacturer's 
instructions. RNAs were DNaseI treated (Ambion) and cDNA was generated with 
SuperScript III (Invitrogen) as previously described 45.  
 
ChIP-qPCR and ChIP-Seq assay 
ChIP was performed as previously described 46.  Briefly, chromatin was first cross-
linked with ethylene glycol bis(succinimidyl succinate) (EGS) in PBS at a final 
concentration of 2 mM for 60 min at RT. Formaldehyde (CH2O) was then added at a 
final concentration of 1 % for 15 min at RT and samples were sonicated over 20 min 
(10 x 30 s pulses) at 4°C to cleave genomic DNA (Bioruptor, Diagenode). Anti-MAZ 
antibody was from Bethyl Laboratories (A301-652A). Real-Time PCR was performed 
using primers and probes (5’FAM-3’TAMRA) for the human α-globin locus described 
previously 10. Each ChIP was performed as two independent experiments and quality 
was assessed by qPCR. The ChIP-seq libraries were prepared using the New England 
Biolabs NEBNext® ChIP-Seq Library Prep Reagent Set for Illumina according to the 
manufacturer’s protocol and starting with between 6 and 40 ng of captured DNA.  All 
libraries received 12 cycles of PCR amplification in the final step before PCR clean-up 
using Ampure beads. Sequencing was carried out on the HiSeq 2500 using Illumina 
HiSeq Rapid Cluster Kit v2 - Paired-End for 100 cycles. RTA software version used 
was Illumina RTA 1.17.20 and the Pipeline software version was  bcl2fastq-1.8.3. 
ChIP-Seq analysis  
Alignment. Reads were aligned using the hisat2 aligner 47 version 2.0.3 with the --no-
spliced-alignment option, but otherwise default parameters, to a splicing-unaware 
index of the human GRCh38 genome. 
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The strength of enrichment in the IP was assessed plotting “fingerprints” using 
deeptools 48 and by calculating normalized strand cross-correlation coefficient (NSC) 
and relative strand cross-correlation coefficient (RSC) metrics using 
Phantompeakqualtools 49. 
Normalisation of the ChIP-Seq signal. Reads of the ChIP-Seq samples were first 
normalised to the input and then scaled to 1x sequencing depth using deepTools v. 
3.1.3 50. 
Peak calling. Peak calling was performed using MACS2 2.1.1 with the minimum FDR 
(q-value) cutoff of 0.01 51.  The top 75% fold enriched peaks were selected for further 
analysis. For ENCODE datasets optimal IDR thresholded peaks provided by the 
ENCODE consortium have been used. 
Peak annotation was made with UCSC RefSeq gene annotation (GRCh38 genome 
version) using HOMER suite 4.8 52. For these analyses we define promoters as 
regions located within a distance of -3000 bp upstream and 100 bp downstream of the 
TSS. 
Coverage analysis and ChIP heatmap plots and profiles were performed using 
DeepTools suites. General genome arithmetics was performed using BEDTools v. 
2.27.1 53. The set of erythroid-specific and housekeeping genes and erythroid 
enhancers was based on 20. 
Correlation of the datasets.  A clustered heatmap of correlation coefficients of bigwig 
signal was computed using the Pearson method; the bam signal combined from the 
replicates was plotted over 10 kb bins with DeepTools. 
Defining erythroid-specific MAZ signal. The peaks called on MAZ datasets were 
overlapped with the peaks from five MAZ ENCODE datasets with the minimum overlap 
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of 1 bp using BEDTools. The MAZ peaks without the overlap in any of the regions 
were assigned to “erythroid-specific peakset”. 
Motif Analysis. To find the sequence motifs enriched in MAZ peaks, genomic 
sequences (from -50 bp to +50 bp around the centres of the top 500 MAZ peaks ranked 
on their q-values) were extracted (hg38) and used as input for MEME de novo motif 
discovery 54 with E-value cutoff 0.01 and motif size defined as 6-30 bp. 
To calculate the presence of the motifs in a given peak, we used FIMO with the above 
defined motifs at a p-value threshold of 10−4 55. Motif central enrichment analysis was 
performed using CentriMo 22 on regions from -250bp to +250 bp relative to the peak 
summits. 
Functional analysis of genes with erythroid-specific MAZ enrichment. g:Profiler 
56 was employed to conduct Gene Ontology (GO) Biological Function and HP (Human 
Phenotype) gene annotations. Fisher's exact test was used to retrieve significantly 
enriched GO terms for genes marked with erythroid-specific MAZ signal. Functional 
categories are defined as those containing at least five genes and a minimum 
enrichment score of 1.3 (p-value < 0.05). GeneATLAS database 17 was used for 
mining MAZ variants associated with erythroid-specific traits (p-value < 10-2).   
Data sources, protocols and analysis. 
Sources of ChIP-seq data are shown in Suppl. Table 6. 
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Figure 1. An erythroid-enriched complex binds a distal element of the HBA 
promoter. (A) Structure of the HBA core and distal promoter elements. The TSS is 
depicted as an angled arrow, and the locations of the EMSA probes are shown as grey 
bars. In vivo DMS footprints detected in K562 and erythroblasts 9 are represented by 
the black boxes. The nucleotide located 18 bp downstream of the TATA box (*) differs 
between the HBA1 (C) and HBA2 (G) promoters. (B) EMSA and supershift assays 
using K562 and EBV nuclear extracts with the indicated probes. (C) The probe 13/14 
binds an additional protein enriched in erythroid cells. (D) Sp/X-KLF-family antibodies 
cause retardation or disruption of the bands (a), (b) and (c), but not (d). 
Figure 2. Identification of MAZ by mass spectrometry. (A) Schematic 
representation of the affinity purification screen. (B) The 10 proteins identified by mass 
spectrometry which were most enriched for binding to the wild type probe relative to 
the mutant. MAZ is highlighted in red. (C) and (D) EMSA showing that the intensity of 
band (d) is dependent on MAZ expression using knockdown (C) or overexpression (D) 
experiments. Knockdown experiments (siRNA) in K562 showed a strong reduction of 
MAZ protein levels and reduction of complex (d) in EMSA assays. Ectopic expression 
of MAZ (SAF1) in COS7 cells strongly enhanced complex (d) in EMSA assays. (E) 
MAZ is recruited to the active a-globin promoter in vivo. Analysis of MAZ binding at 
the a-globin locus in EBV-lymphoblasts, K562 cells and human primary erythroid cells 
by ChIP-qPCR. The y axis represents enrichment over the input DNA, normalised to 
a control sequence in the human 18S gene. The x axis indicates the Taqman probes 
used. The position of probes within the a-globin cluster are indicated on the heading 
map. The α-globin genes themselves are covered by three probes (Pr/Ex1, Ex2, Ex3). 
Error bars correspond to one SEM from two independent ChIPs. 
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Figure 3. MAZ Knockdown impairs erythropoiesis. (A) Flow cytometry analysis of 
CD71 and GPA expression at day 15 of representative primary erythroblast 
differentiation cultures infected with lentivirus expressing scramble shRNA or MAZ 
shRNA. In scramble shRNA cultures, cells progress towards a CD71+GPA+ phenotype 
whereas shRNA against MAZ blocked differentiation at CD71 single positive cells. (B) 
Quantitation of flow cytometry staining as demonstrated in (A). Shown is the mean 
and standard deviation from two independent differentiation cultures. (C) Cell pellets 
from primary cultures at d15 of differentiation. Cultures with the MAZ shRNA are more 
pale, indicating less extensive hemoglobinisation. (D) Real-time RT-PCR analysis of 
expression of MAZ, HBA1, HBA2 and HBB after 15 d of primary erythroid 
differentiation cultures. Shown is the mean and standard deviation from two 
independent differentiation cultures.  For each gene, expression (relative to the 
GAPDH) is normalized to the mean value observed with scramble shRNA. (E) Variants 
around the MAZ locus significantly associated with clinical erythroid traits (p-value <10-
2).  
Figure 4. MAZ is enriched at active TSS and binds to DNA through a (G)3C(G)4 
consensus site. (A) MAZ ChIP-seq enrichment profiles for the α- and β-globin loci. 
(B) Genomic distribution of MAZ binding sites showing the number of peaks 
overlapping the category of genomic element indicated. (C) Heatmap plots of ATAC-
seq, H3K4me3, H3K27ac, Pol II and H3K27me3 signal centred on MAZ peaks in 
erythroblasts cells (sorted according to decreasing MAZ ChIP signal). (D) 
Characteristics of DNA motifs significantly enriched (E<0.01) in MAZ peaks. (E) Motif 
localisation curves relative to the MAZ peak centres. The numbers of the enriched 
motifs correspond to the logos in (D).  
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Figure 5. Analysis of erythroid-specific MAZ signal. (A) Heatmap plots of MAZ 
ChIP-seq datasets from six cell types centered on MAZ common and cell-line-specific 
peaksets. Numbers on left indicate the common peaks (1), and peaks specific to 
erythroblasts (2), HepG2 (3), A549 (4), GM12878 (5), MCF-7 (6) and IMR90 (7) cells. 
(B) Pearson correlation analysis of MAZ ChIP-seq datasets from the six cell types. (C) 
Gene ontology (by biological function) of genes with erythroid-specific MAZ signal. (D) 
Human Phenotype Ontology of genes with erythroid-specific MAZ signal. 
Figure 6. Erythroid-specific MAZ signal is enriched on GATA1-bound enhancers. 
(A) Genome distribution of MAZ common and erythroid-specific binding sites. (B) 
Average H3K4me1, H3K4me3, MAZ and ATAC-seq signal in primary erythroid cells 
plotted against MAZ erythroid-specific peakset (black) and MAZ common peakset 
(red) where signal from promoters have been excluded (non-TSS set). (C) Left panel: 
Heatmap plot of GATA1 ChIP-seq centred on MAZ erythroid peaks overlapping 
enhancers (top) and promoters (bottom). Right panel: Heatmap plot of MAZ ChIP-seq 
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Gel shift results 
1/2 -37/-19 TATA box No shifted species 
3/4 -56/-39 α-IRP -51/-42 site Shifted species detected in EBV and K562 
5/6 -67/-50 Sp1 -61/-56 site No shift 
7/8 -78/-61 CBF -72/-65 site Shifted species detected in EBV and K562 
Binding impaired by α-CBF antibody  
9/10 -88/-72 NF1 -85/-72 site Shifted species detected in EBV and K562 
Binding impaired by α-NF1 antibody 
11/12 -100/-83  Three shifted species detected in EBV and K562 
One shifted species only in K562 
13/14 -128/-111 Sp1 -121/-116 site Three shifted species detected in EBV and K562 
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Family with sequence similarity 139, member A;
Putative uncharacterized protein FLJ40722;
100.9 28.66067999
GNL3; E2IG3; NS
Guanine nucleotide-binding protein-like 3;
Nucleolar GTP-binding protein 3; Nucleostemin; 
E2-induced gene 3 protein; Novel nucleolar protein 47; NNP47
62.0 27.56177032
ANKK1; PKK2; SGK288
Ankyrin repeat and protein kinase domain-containing protein 1;
Protein kinase PKK2; X-kinase; Sugen kinase 288; SgK288 84.632 21.63577185
ZCCHC17; PS1D; HSPC243; 
HSPC251; LDC4
Nucleolar protein of 40 kDa; pNO40; 
Zinc finger CCHC domain-containing protein 17;
Putative S1 RNA-binding domain protein; PS1D protein; 
Pnn-interacting nucleolar protein
27.6 21.54945043
NOL1 Putative RNA methyltransferase NOL1; Proliferating-cell nucleolar antigen p120; Proliferation-associated nucleolar protein p120; Uncharacterized protein NOL1 92.9 20.70552404
RPS8; OK/SW-cl.83; RP11-
269F19.3-003 40S ribosomal protein S8; Ribosomal protein S8 25.2 14.60330352
MAZ MAZ protein; Myc-associated zinc finger protein;MAZI; Purine-binding transcription factor; Pur-1; ZF87; ZIF87 51.1 14.26242555
SURF6; SURF-6 Surfeit locus protein 6 41.5 14.03328268
HIST1H1D; H1F3 Histone H1.3; Histone H1c 22.4 10.88943545
HIST1H1E; H1F4 Histone H1.4; Histone H1b 21.9 9.228533738
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VARIANT LOCATION IN THE MAZ REGION ERYTHROID TRAIT P-VALUE 
RS572982482 MAZ promoter Haematocrit percentage 3.54E-03
Haemoglobin concentration 7.30E-03
Mean reticulocyte volume 9.66E-03
Red blood cell (erythrocyte) count 1.96E-04
Reticulocyte count 4.85E-04
Reticulocyte percentage 4.63E-03
RS72798129 intron variant Mean reticulocyte volume 1.97E-05
Mean sphered cell volume 8.94E-03
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